Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.

Mark J Sarnak, Kerstin Amann, Sripal Bangalore, João L Cavalcante, David M Charytan, Jonathan C Craig, John S Gill, Mark A Hlatky, Alan G Jardine, Ulf Landmesser, L Kristin Newby, Charles A Herzog, Michael Cheung, David C Wheeler, Wolfgang C Winkelmayer, Thomas H Marwick

Journal: Journal of the American College of Cardiology 2020;74(14):1823-1838

PMID: 31582143

Free Full Text on Elsevier Science View on PubMed

Abstract

Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.

Address: Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. Electronic address: [email protected].; Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany.; Division of Cardiology, New York University School of Medicine, New York, New York.; Minneapolis Heart Institute, Minneapolis, Minnesota.; Division of Nephrology, New York University School of Medicine, New York, New York.; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.; Division of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.; Department of Cardiology, Charité Universitätsmedizin, Berlin, Germany.; Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.; Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota; Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota.; Kidney Disease: Improving Global Outcomes, Brussels, Belgium.; University College London, London, United Kingdom.; Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address: [email protected].

DOI: 10.1016/j.jacc.2019.08.1017